The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...

Researchers leading a trial of active surveillance for ductal carcinoma in situ (DCIS) have described early results as "reassuring" in a presentation at the 15th European Breast Cancer Conference ...

FRIDAY, Dec. 13, 2024 (HealthDay News) -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or ...

BARCELONA, Spain — Active monitoring may be a feasible alternative to immediate surgery for some women with low-risk ductal carcinoma in situ (DCIS), but results from two phase 3 studies presented at ...

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (ATOS) (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address ...

An international team of researchers led by the Netherlands Cancer Institute developed a method to better predict the outgrowth of ductal carcinoma in situ (DCIS), a possible precursor of breast ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is typically ...

A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. This is an ...